Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05413421 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2025 to Jun 2027 Enrollment target: 250 to 275 · Completion date: Sep 2026 to Apr 2028v10 Show 2 more changesShow less
    • Enrollment target: 250 to 275
    • Completion date: Sep 2026 to Apr 2028
  2. Study sites: 16 to 27v9
  3. Primary completion date: Dec 2024 to Dec 2025v8
  4. Study sites: 13 to 16v7
  5. Enrollment target: 42 to 250 Primary completion date: May 2023 to Dec 2024 · Study sites: 6 to 13 · Completion date: Jun 2024 to Sep 2026 · 5 morev6 Show 8 more changesShow less
    • Primary completion date: May 2023 to Dec 2024
    • Study sites: 6 to 13
    • Completion date: Jun 2024 to Sep 2026
    • Interventions: ORIC-944 (Drug) to Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets (Drug), Apalutamide (Erleada™) 60 mg or 240 mg tablets (Drug), Darolutamide…
    • Eligibility criteria expanded, about 88 words
    • Secondary endpoints: 4 to 5
    • Study description shortened, about 23 words
    • Study arms: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 3 to 6v5
  2. Start date changed from estimate of Jun 2022 to Jun 1, 2022 Site contacts updated at 1 of 3 sitesv4 Show 1 more changeShow less
    • Site contacts updated at 1 of 3 sites
  3. Trial status: Not Yet Recruiting to Recruiting Site details revised at 3 of 3 sitesv3 Show 1 more changeShow less
    • Site details revised at 3 of 3 sites
  4. Study sites: 0 to 3v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Trial Details
NCT Number NCT05413421
Lead Sponsor ORIC Pharmaceuticals
Conditions Metastatic Prostate Cancer
Enrollment 275 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov